ArticleWorld journal of transplantation2026
Rethinking procurement biopsy in donors with normal renal function: A barrier to kidney utilization without survival benefit.
Article in World journal of transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Time-Zero Kidney Biopsy and Deceased-Donor Transplant Outcomes: A Systematic Review and Meta-Analysis of Prognostic Value, Prediction, and Clinical Utility.Medical sciences (Basel, Switzerland) · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProcurement biopsy remains widely used in deceased donor kidney transplantation, yet its value is uncertain in kidneys with preserved renal function. Concerns persist regarding sampling error, interpretive variability, and the potential for biopsy findings to contribute directly to organ discard. Whether procurement biopsy improves decision-making or graft outcomes in donors with normal renal function is not known.
aimTo investigate whether biopsy adds clinical value or causes delay, misclassification without improving outcomes in donors with preserved renal function.
methodsUsing national Organ Procurement and Transplantation Network data (2014-2024), we evaluated deceased donor kidneys with terminal epidermal growth factor receptor ≥ 60. Donor, recipient, and transplant variables were linked at the center level to reflect clinical decision pathways. Propensity-score matching (1:1 nearest neighbor, caliper 0.2 SD) generated balanced biopsy and non-biopsy cohorts. Center-clustered Cox models estimated the association between biopsy and death-censored graft failure. Mediation through cold ischemia time and delayed graft function was examined using sequential attenuation, with robustness assessed
resultsOf 158365 recovered kidneys, 46.6% underwent biopsy and were over six times more likely to be discarded (28.2%
conclusionIn deceased donors with normal renal function, procurement biopsy adds no prognostic value, increases discard and ischemic delay, and may hinder optimal utilization of otherwise transplantable kidneys.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.